Zenas BioPharma

Contributing Author

Recent Articles by Zenas BioPharma

Jun-02	Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine ZBIO -5.72% GlobeNewswire
May-28	Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD ZBIO GlobeNewswire
May-19	Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress ZBIO +5.50% GlobeNewswire
May-18	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO -7.80% GlobeNewswire
May-13	Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor ZBIO GlobeNewswire
May-13	Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update ZBIO GlobeNewswire
Apr-17	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
Mar-27	Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million ZBIO -17.82% GlobeNewswire
Mar-26	Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock ZBIO GlobeNewswire
Mar-16	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
Mar-16	Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update ZBIO GlobeNewswire
Feb-20	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
Feb-09	Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 ZBIO GlobeNewswire
Feb-04	Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 ZBIO GlobeNewswire
Jan-16	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
Jan-05	Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) ZBIO -51.86% GlobeNewswire
Dec-19	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO +17.10% ZBIO GlobeNewswire
Dec-15	Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus ZBIO -19.71% GlobeNewswire
Nov-12	Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update ZBIO GlobeNewswire
Nov-11	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences ZBIO +8.41% GlobeNewswire
Oct-27	Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis ZBIO +33.08% GlobeNewswire
Oct-08	Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis ZBIO +24.22% GlobeNewswire
Sep-02	Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million ZBIO +9.50% GlobeNewswire
Aug-26	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences ZBIO GlobeNewswire
Aug-12	Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates ZBIO +6.68% GlobeNewswire
Jun-20	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
May-29	Zenas BioPharma to Present at the Jefferies Global Healthcare Conference ZBIO +8.34% GlobeNewswire
May-15	Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates ZBIO +12.21% GlobeNewswire

Zenas BioPharma

Recent Articles by Zenas BioPharma

Upgrade your Finviz experience